Rallybio Corporation (NASDAQ:RLYB – Get Free Report) declared a special dividend on Sunday, October 25th. Investors of record on Thursday, November 5th will be paid a dividend of $13.56 per share on Friday, November 13th.
Rallybio Price Performance
RLYB traded down $0.72 during trading on Tuesday, reaching $15.93. 52,619 shares of the stock were exchanged, compared to its average volume of 123,699. The company has a market capitalization of $84.59 million, a price-to-earnings ratio of -3.67 and a beta of -0.72. Rallybio has a 1 year low of $3.67 and a 1 year high of $17.57. The business’s 50 day moving average price is $16.82 and its two-hundred day moving average price is $12.67.
Rallybio (NASDAQ:RLYB – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.48) earnings per share for the quarter. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.
Rallybio Company Profile
Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.
Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.
Further Reading
- Five stocks we like better than Rallybio
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
